22198-Lung Cancer-NA-1551

Lung Cancer

(FURMO-004) A Global, Phase 3, Randomized, Multicenter, Open-Label Study to Investigate the Efficacy and Safety of Furmonertinib Compared to Platinum-Based Chemotherapy as First-Line Treatment for Patients with Locally Advanced or Metastatic Non-Small Cell Lung Cancer with Epidermal Growth Factor Receptor Exon 20 Insertion Mutations

  • Details

ClinicalTrials.gov ID: NCT05607550
Diagnosis Type: NA
USOR Number:

  • Address

444 NW Elks Drive
Corvallis, OR 97330
P: (541) 683-5001

Search by practice name, trial titles, indicators and specific disease types.